RxMP Therapeutics, Inc.

RxMP Therapeutics, Inc. (“RxMP”) is an emerging, specialty therapeutics company focused on developing proprietary therapeutics for the management of hemorrhage and excessive bleeding. Hemorrhage and excessive bleeding remain life-threatening challenges in many areas of medical practice, especially in surgical procedures, trauma care, in the brain and other organs. RxMP aims to develop and commercialize red cell-derived microparticles produced by high-pressure extrusion (“RMP-HPEs”) as a novel first-in-class systemic hemostatic agent for the treatment or prevention of hemorrhage and excessive bleeding. In addition, by mechanism, these therapies will have low risk for serious off-target adverse events (e.g. thrombosis). Our product’s initial target markets include: 1) those patients at risk of excessive bleeding during surgery and 2) those patients suffering spontaneous intracerebral hemorrhage, an Orphan Drug indication.